x min read

Nutra Pharma Corp. (OTCMKTS:NPHC) Looks Set To Fly Higher

Nutra Pharma Corp. (OTCMKTS:NPHC) Looks Set To Fly Higher
Written by
Jarrod Wesson
Published on
July 14, 2017
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Shares of Nutra Pharma Corp. (OTCMKTS:NPHC) exploded higher recently after the company announced the launch of Luxury Feet in June, 2017. The presentation of the product, an over-the-counter pain reliever and anti-inflammatory product, seems to be a catalyst for the stock. The volume increased little by little after the news was out. If the purchase orders continue, the share price may commence an upward trend. Have a look at the most recent share price action. We will try to explain what's going on in this article.SourceNutra PharmaSourceThe company was founded in California on February 1, 2000. The business objective is the following:

"We are a biopharmaceutical company that engages in the acquisition, licensing and commercialization of pharmaceutical products and technologies as well as homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, autoimmune and infectious diseases.". Source

NPHC states in its documents that it seeks partnerships with other companies to reduce operational risks. The company has a subsidiary. Namely ReceptoPharm, which is in charge of the research and development. It has developed the following drugs:

  • Nyloxin® and Nyloxin® Extra Strength
  • Pet Pain-Away: an OTC pain reliever that treats pain in cats and dogs

The day-to-day operations of the company consist of the production, marketing, and distribution of Nyloxin ® and Pet Pain-Away in the US and other countries.The following is a video, wherein Nyloxin is explained:https://youtu.be/G-wtgBuuApYAdditionally, the following drugs are candidates owned by NPHC

  • RPI-78M: is a treatment of neurological diseases and autoimmune diseases.
  • RPI-MN: is a treatment of viral diseases, including HIV/AIDS and Herpes.

Recent DevelopmentsOn June 21, 2017, it put out the introduction of the new product “Luxury Feet”, which is an "over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos". Rik J Deitsch, CEO of NPHC, explained that the product will treat women suffering from foot problems caused by the use of high heels. The demand may be very significant if the product is successful.

"Women who chronically wear high heels are prone to a variety of foot problems, including pain, bunions, hammer toe and Plantar fasciitis. We know that women spend upwards of $600 for a pair of shoes and certainly would like to wear them without fear of pain." Source

The American Podiatric Medical Association reported very interesting stats about the use of high-heeled shoes. These numbers helped the marketing professionals measure the potential demand for Luxury Feet.

  • "72% of women wear high-heeled shoes,
  • 58% of women purchased new high-heeled shoes in the last year,
  • 59% report toe pain as a result of wearing uncomfortable shoes while 54% report pain in the ball of the foot. " Source

Additionally, on May 31, 2017, NPHC put out its collaboration with the University of Maryland Bioprocess Scale-Up Facility (BSF) to "optimize manufacturing processes for the production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis". We believe that this is a great news. NPHC seems to have drug candidate that has drawn the attention of researchers at the University. They will help the company prepare for phase II. Hence, be ready for new announcements. The company has been already granted an Orphan Designation from the US-FDA, thus the next thing may be the Phase II approval. Dale Vander Putten, PhD, Nutra Pharma's Chief Scientific Officer, explained the state of the study with the following words:

"Based on our pre-clinical and open-label clinical studies, we believe that RPI-78M has the ability to successfully navigate the FDA approval process. We believe that a recombinant product will ultimately provide these kids with the best possible drug. We are now working with the BSF to scale up drug manufacturing in preparation for the upcoming Phase II clinical trials," Source

The company has a media presenceThe company has appeared in many channels presenting the drugs. It seems that many people in the media are calling NPHC to invite the directors talk. On June 7, 2017, the company was featured in the Spanish channel Univision, and on March 14, 2017, Stockguru.com contacted the CEO to introduce NPHC on the website. We appreciate the work of the investor relations team, and the fact that these shows will increase investors' awareness. It is also relevant that the public believes that the drug candidates will be useful. Television channels would have not contacted the company, if that wasn't true.Insiders and shareholdersWe could see that some shareholders had to declare their stakes in the company. Have a look:HolderSharesDate Reported% OutValueFisher Asset Management, LLC100,063Mar 30, 20170.03%500SourceConclusionNPHC is interesting for three facts. First of all, the company is already selling two drugs in the United States, and the products are known by the public. But, that's not all. The company recently delivered interesting news about a collaboration with a University, which will help the company present documents for the Phase II approval. This is a catalyst. If the company is able to receive the FDA approval for the drug RPI-78M the stock will most likely jump. In addition, the market may be interested in the revenues reported by the new product; the Luxury Feet. Hence, we need to follow the stock closely. Subscribe to our newsletter if you need rapid information an assessment of breaking news from NPHC.We will updating out subscribers as soon as we know more. For the latest updates on NPHC, sign up below!Image courtesy of castrospad via FlickrDisclosure: We have no position in NPHC and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.